The sudden retirement of Richard Padzdur, a senior drug regulatory officer at the US Food and Drug Administration, raised questions about cancer drug review timelines and priorities. Analysts say big pharmaceutical companies such as Merck will be affected by this incident.

The sudden retirement of Richard Padzdur, a senior drug regulatory officer at the US Food and Drug Administration, raised questions about cancer drug review timelines and priorities. Analysts say big pharmaceutical companies such as Merck will be affected by this incident.